In Vitro and in Vivo Efficacy of NBDHEX on Gefitinib-resistant Human Non-small Cell Lung Cancer

Gefitinib, a first-generation EGFR tyrosine kinase inhibitor (EGFR-TKI), is recommended for treatment of non-small cell lung cancer (NSCLC) patients who harbor activating EGFR mutations. However, the tumors of most patients initially sensitive to gefitinib will develop resistance within several mont...

Descripción completa

Detalles Bibliográficos
Autores principales: Sha, Huanhuan, Dong, Shuchen, Yu, Chen, Zou, Renrui, Zhu, Yue, Lu, Ya, Zhang, Junying, Cao, Haixia, Chen, Dan, Wu, Jianzhong, Feng, Jifeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7646187/
https://www.ncbi.nlm.nih.gov/pubmed/33193885
http://dx.doi.org/10.7150/jca.46461

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7646187/
https://www.ncbi.nlm.nih.gov/pubmed/33193885
http://dx.doi.org/10.7150/jca.46461

Ejemplares similares